ThromboGenics completes patient enrollment of MITI IV Trial, a phase II study evaluating the safety and preliminary efficacy of microplasmin in the treatment of acute stroke

http://www.thrombogenics.com/documents/08_TG_06MITIIVEnrolCompleteFinalEN.pdf

Comments are closed.